{
  "id": "consort-2010",
  "title": "CONSORT 2010 Checklist",
  "items": [
    {
      "section": "Instructions",
      "item": "Use the boxes to confirm each reporting item."
    },
    {
      "section": "Instructions",
      "item": "Add reviewer notes under each section as needed."
    },
    {
      "section": "Title and Abstract",
      "item": "**1a. Title:** Identification of the trial as randomised."
    },
    {
      "section": "Title and Abstract",
      "item": "**1b. Abstract:** Structured summary of trial design, methods, results, and conclusions."
    },
    {
      "section": "Introduction",
      "item": "**2a. Background:** Scientific background and explanation of rationale."
    },
    {
      "section": "Introduction",
      "item": "**2b. Objectives:** Specific objectives or hypotheses."
    },
    {
      "section": "Methods",
      "item": "**3a. Trial design:** Description of trial design (e.g., parallel, factorial) including allocation ratio."
    },
    {
      "section": "Methods",
      "item": "**3b. Changes to trial design:** Important changes to methods after trial commencement (such as eligibility criteria), with reasons."
    },
    {
      "section": "Methods",
      "item": "**4a. Participants:** Eligibility criteria for participants."
    },
    {
      "section": "Methods",
      "item": "**4b. Study settings:** Settings and locations where the data were collected."
    },
    {
      "section": "Methods",
      "item": "**5. Interventions:** The interventions for each group with sufficient details to allow replication, including how and when they were actually administered."
    },
    {
      "section": "Methods",
      "item": "**6a. Outcomes:** Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed."
    },
    {
      "section": "Methods",
      "item": "**6b. Changes to outcomes:** Any changes to trial outcomes after the trial commenced, with reasons."
    },
    {
      "section": "Methods",
      "item": "**7a. Sample size:** How sample size was determined."
    },
    {
      "section": "Methods",
      "item": "**7b. Interim analyses and stopping guidelines:** When applicable, explanation of any interim analyses and stopping guidelines."
    },
    {
      "section": "Methods",
      "item": "**8a. Randomisation: sequence generation:** Method used to generate the random allocation sequence."
    },
    {
      "section": "Methods",
      "item": "**8b. Randomisation: type:** Type of randomisation; details of any restriction (e.g., blocking and block size)."
    },
    {
      "section": "Methods",
      "item": "**9. Allocation concealment mechanism:** Mechanism used to implement the random allocation sequence (e.g., sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned."
    },
    {
      "section": "Methods",
      "item": "**10. Implementation:** Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions."
    },
    {
      "section": "Methods",
      "item": "**11a. Blinding:** If done, who was blinded after assignment to interventions (e.g., participants, care providers, those assessing outcomes) and how."
    },
    {
      "section": "Methods",
      "item": "**11b. Similarity of interventions:** If relevant, description of the similarity of interventions."
    },
    {
      "section": "Methods",
      "item": "**12a. Statistical methods:** Statistical methods used to compare groups for primary and secondary outcomes."
    },
    {
      "section": "Methods",
      "item": "**12b. Additional analyses:** Methods for additional analyses, such as subgroup analyses and adjusted analyses."
    },
    {
      "section": "Results",
      "item": "**13a. Participant flow (a diagram is strongly recommended):** For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome."
    },
    {
      "section": "Results",
      "item": "**13b. Losses and exclusions:** For each group, losses and exclusions after randomisation, together with reasons."
    },
    {
      "section": "Results",
      "item": "**14a. Recruitment:** Dates defining the periods of recruitment and follow-up."
    },
    {
      "section": "Results",
      "item": "**14b. Reason for stopping:** Why the trial ended or was stopped."
    },
    {
      "section": "Results",
      "item": "**15. Baseline data:** A table showing baseline demographic and clinical characteristics for each group."
    },
    {
      "section": "Results",
      "item": "**16. Numbers analysed:** For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups."
    },
    {
      "section": "Results",
      "item": "**17a. Outcomes and estimation:** For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)."
    },
    {
      "section": "Results",
      "item": "**17b. Binary outcomes:** For binary outcomes, presentation of both absolute and relative effect sizes is recommended."
    },
    {
      "section": "Results",
      "item": "**18. Ancillary analyses:** Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory."
    },
    {
      "section": "Results",
      "item": "**19. Harms:** All important harms or unintended effects in each group."
    },
    {
      "section": "Discussion",
      "item": "**20. Limitations:** Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses."
    },
    {
      "section": "Discussion",
      "item": "**21. Generalisability:** Generalisability (external validity, applicability) of the trial findings."
    },
    {
      "section": "Discussion",
      "item": "**22. Interpretation:** Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence."
    },
    {
      "section": "Other Information",
      "item": "**23. Registration:** Registration number and name of trial registry."
    },
    {
      "section": "Other Information",
      "item": "**24. Protocol:** Where the full trial protocol can be accessed, if available."
    },
    {
      "section": "Other Information",
      "item": "**25. Funding:** Sources of funding and other support (such as supply of drugs), role of funders."
    },
    {
      "section": "Provenance",
      "item": "Source: See sidecar metadata in `source/archetypes/consort-2010.yml`"
    },
    {
      "section": "Provenance",
      "item": "Version: 2010"
    },
    {
      "section": "Provenance",
      "item": "License: CC BY 4.0"
    }
  ]
}